Carbon-11 dimethyl diphenyl ammonium

Drug Profile

Carbon-11 dimethyl diphenyl ammonium

Alternative Names: [11C]-DMDPA; C11 DMDPA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hadassah Medical Organization
  • Developer Hadassah Medical Organization; Synektik S.A
  • Class Imaging agents; Radiopharmaceutical diagnostics; Vascular disorder therapies
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery disease

Most Recent Events

  • 13 Oct 2017 Phase-II clinical trials in Coronary artery disease (Diagnosis) in Poland (IV) (EudraCT2017-002055-28)
  • 01 May 2017 Synektek and Hadassah Medical Organization complete a phase I trial in Coronary artery disease (Diagnosis, In volunteers) in Poland and Israel (NCT02720354)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top